November 6th, 2014
Agent Could Potentially Reverse Anticoagulation Associated with Edoxaban
PER977 — a cation that binds to all of the new oral anticoagulants and heparin — may help reverse the anticoagulant effects of edoxaban, according to results of an industry-conducted trial published in the New England Journal of Medicine. Edoxaban, an oral factor Xa inhibitor, was recently recommended for approval by an FDA advisory panel. […]
November 4th, 2014
Nonobstructive Coronary Artery Disease Linked to Elevated Risk
Larry Husten, PHD
A large number of people who undergo elective coronary angiography are found to have nonobstructive coronary artery disease, and these patients have significantly increased risk for myocardial infarction and death, according to a retrospective study published in JAMA. Thomas Maddox and colleagues analyzed data from nearly 38,000 elective angiography patients in the VA health system. More […]
November 3rd, 2014
AF Patients at Increased Risk for Silent Strokes
Larry Husten, PHD
The increased risk of stroke in people with atrial fibrillation (AF) is well known, and this stroke risk is, of course, linked to an increased risk of cognitive impairment and dementia. Less well known is that people with AF have an increased risk for cognitive impairment independent of their stroke risk. Now a new study […]
November 3rd, 2014
A “Big Data” Approach to Phenotype-Based Clustering of Heart Failure Patients
Tariq Ahmad, MD, MPH
Tariq Ahmad discusses his research group’s study of clinical phenotypes in patients with chronic systolic heart failure.
November 3rd, 2014
Selections from Richard Lehman’s Literature Review: November 3rd
Richard Lehman, BM, BCh, MRCGP
This week’s topics include dual-antiplatelet treatment beyond one year after DES implantation, reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome, and more.
November 3rd, 2014
Economic Study Finds VTE Prophylaxis with Low-Molecular-Weight Heparin Cost Effective
Larry Husten, PHD
Critically ill patients in the hospital are at high risk for developing venous thromboembolism (VTE). The 2011 PROTECT trial compared the two most common drug strategies used to prevent VTE — unfractionated heparin (UFH) and dalteparin, a low-molecular-weight heparin (LMWH) — and found no difference between the two groups in the primary endpoint of the trial, leg deep-vein thrombosis. […]